Phenoxypropazine

Last updated
Phenoxypropazine
Phenoxypropazine skeletal.svg
Clinical data
Routes of
administration 		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (1-methyl-2-phenoxy-ethyl)hydrazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C9H14N2O
Molar mass 166.224 g·mol−1

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns. [1] [2] [3] [4] [5]

See also

References

  1. ↑ LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression" . The American Journal of Psychiatry. 119 (10): 986–7. doi:10.1176/ajp.119.10.986. PMID   13928824.
  2. ↑ IMLAH NW (May 1963). "Preliminary report on phenoxypropazine" . The American Journal of Psychiatry. 119 (11): 1091–2. doi:10.1176/ajp.119.11.1091. PMID   13956423.
  3. ↑ ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression" . The American Journal of Psychiatry. 120 (4): 393–5. doi:10.1176/ajp.120.4.393. PMID   14069469.
  4. ↑ ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression" . The American Journal of Psychiatry. 120 (9): 899–900. doi:10.1176/ajp.120.9.899. PMID   14129290.
  5. ↑ MCWHINNEY IR, MORRELL DC (January 1965). "Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice". The Journal of the College of General Practitioners. 9 (1): 95–9. PMC   1878242 . PMID   14254271.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.